Cardiovascular pharmacotherapy is the cornerstone on which our approach to the management of patients with cardiovascular disease is based.
In recent years there have been a number of key breakthroughs which have transformed the way we treat our patients – highly effective and superior antithrombotic drugs for acute and chronic coronary syndromes, novel direct anticoagulants (NOACS) for stroke prevention in the patient with atrial fibrillation and for the management of venous thromboembolic disease, a whole new world of lipid lowering therapy for primary and secondary prevention and new antidiabetic therapy which significantly improves long-term clinical outcome and reduces mortality. Very importantly, there has also been landmark progress in the development of new drugs to better address the ever-challenging problem of heart failure.
EuroCVP 2018, the 6th Annual Congress of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, will be held in Tel Aviv on 13-14 May, 2018. EuroCVP 2018 will provide up to date discussions regarding the clinical applicability and significance of new drugs and new data. The congress will feature high quality plenary and keynote lectures, focused debates in topical areas of therapy and a large number of free communications which will be presented in e-poster and guided poster sessions.
A special attraction at ESC 2018 will be the very popular ESC educational course “All About Clinical Trials”, to be held in conjunction with the main congress program. The trials program will not only give a focused view of the clinical trial arena with workshops in trial interpretation and analysis, but will also give a state of the art update of what is new and coming in clinical trials. It will include a good clinical practice update course and GCP certificate.
We urge you to attend EuroCVP 2018 and to be part of these game-changing areas in cardiovascular therapeutics.
We also look forward very much to welcoming you to the exciting and vibrant city of Tel Aviv in May 2018.